Bristol Myers, Exelixis announce Opdivo in combo with Cabometyx shows durable survival with over 3 years of follow-up in CheckMate -9ER trial in first-line advanced RCC

Press/Media

Period	15 Feb 2023

Media coverage

Title	Bristol Myers, Exelixis announce Opdivo in combo with Cabometyx shows durable survival with over 3 years of follow-up in CheckMate -9ER trial in first-line advanced RCC
Media name/outlet	PharmaBiz
Country/Territory	India
Date	15/02/23
URL	ct.moreover.com/?a=50017825566&p=1gw&v=1&x=qyxZyfBi-VdO4YqE8_fs0g
Persons	Mauricio Burotto